欢迎来到天天文库
浏览记录
ID:54923657
大小:696.45 KB
页数:5页
时间:2020-05-04
《应用全肝CT灌注技术评价原发性肝癌血流灌注特点及其相关因素分析-论文.pdf》由会员上传分享,免费在线阅读,更多相关内容在应用文档-天天文库。
1、现代肿瘤医学2014年5月第22卷第5期MODERNONCOLOGY,May.2014,VOL.22,NO.05者分组给予膀胱灌注的临床研究表明,应用吡柔比星30mg/tionofpirambicinagainstsuperficialbladdercaucer:relationshipbetweentumortissueconcen~afionandexposuretimeintheblad-5Oral(600txg/m1),给予术后早期膀胱灌注,膀胱腔内保留4O一60min,并进行为期2年的短期疗程,对于预防非肌层浸润derortherapeutic
2、efect[J].ExpTherMed,2011,2(5):901—905.性膀胱肿瘤TUR—BT术后复发效果明显优于单纯常规膀胱[7]TochigiT,SakuradaY,AokiH,eta1.Theintravesicalrecurrence灌注,且不增加局部及全身不良反应的发生率。由于作者观after3一dayconsecutiveintravesicalinstillationofpirarubicine察的临床病例较少,术后随访时间也不长。因此临床疗效仍hydrochloride(THP)followingtransurethralresect
3、ionofbladder需要更多病例的累积和更长时间的观察,以进一步验证吡柔tumor(TUR—BT)fornon—muscle—invasivebladdercancer[J].比星早期膀胱灌注在rUR—BT术后降低非肌层浸润性膀胱NihonHinyokikaGakkaiZasshi,2012,103(4):610—616.肿瘤复发的安全性及有效性。[8]CooksonMS,ChangSS,OefeleinMG,eta1.Nationalpracticepat—【参考文献】ternsforimmediatepostoperativeinstillati
4、onofchemotherapyin[1]FerrisJ,BerbelO,Alonso—L6pezJ,eta1.Environmentalnon—oc-nonmuscleinvasivebladdercancer[J].JUrol,2012,187(5):cupafonalriskfactomassociatedwithbladdercancer[J].Actas1571—1576.UmlEsp,2013,37(9):579—586.[9]BurksFN,LiuAB,SuhRS,eta1.Understandingtheuseofimmedi—[2j陈俊
5、星,尧智军,丘少鹏,等.TIG膀胱癌保留膀胱术后动脉导ateintravesicalchemotherapyforpatientswithbladdercancer[J].J管化疗联合膀胱灌注化疗的疗效分析[J].中华泌尿外科杂Urol,2012,188(6):2108—2113.志,2012,33(2):99—103.[10]MaruyamaT,HiguchiY,SuzukiT,eta1.Doublesh0n—timeexposure[3]NargundVH,TanabalanCK,KabirMN.Managementofnon—mus-topirar
6、ubicinproduceshighercytotoxicityagainstT24bladdercle—invasive(superficia1)bladdercancer[J].SeminOncol,cancercells[J】.JInfectChemother,2011,17(1):11—16.2012,39(5):559—572.1t0A,ShintakuI,SatohM,eta1.ProspectiverandomizedphaseII[4]EldefrawyA,SolowayMS,KatkooriD,eta1.Neoadjuvantandad
7、ju-trialofasingleearlyintravesicalinstillationofpirarubicin(THP)rantchemotherapyformuscle—-invasivebladdercancer:thelikeli-inthepreventionofbladderrecurrenceafternephroureterectomyhoodofinitiationandcompletion[J].IndianJUrol,2012,28(4):forupperurinarytracturothelialcarcinoma:theT
8、HPMonotherapy424—426.StudyGroupTrial[J].
此文档下载收益归作者所有